Volume 6, Issue 2 (Journal of Clinical and Basic Research (JCBR) 2022)
jcbr 2022, 6(2): 1-11 |
Back to browse issues page
1- Department of Immunotherapy and Vaccine Research, Pasteur Institute of Iran, Tehran, Iran
2- Department of Microbiology, School of Medicine, Golestan University of Medical Sciences, Gorgan, Iran
3- Vista Aria Rena Gene Inc., Golestan Province, Gorgan, Iran , Mohebbi-a@goums.ac.ir
2- Department of Microbiology, School of Medicine, Golestan University of Medical Sciences, Gorgan, Iran
3- Vista Aria Rena Gene Inc., Golestan Province, Gorgan, Iran , Mohebbi-a@goums.ac.ir
Abstract: (1678 Views)
Background and objectives: Cancer stem cells (CSCs) may contribute to tumor initiation, distant metastasis, and chemo-resistance. Quaking (QKI) is a RNA binding protein, a tumor suppressor, and a well-known stem cell biomarker in central nervous system (CNS) cancer. The aim of this study was to identify the potential of QKI mRNA as a prognostic marker for CNS cancer.
Methods: The Cancer Genome Atlas (TCGA) was investigated for gene expression profile within CNS cancer data. Further analysis was done through cBioPortal and COSMIC to explore the QKI gene mutation(s). Moreover, QKI mRNA levels were evaluated by using SAGE Genie tools. The Kaplan-Meier Plotter was utilized to identify prognostic role of QKI mRNA levels in these cancers.
Results: Higher levels of QKI mRNA were detected in brain cancer tissues. Altered QKI gene expression was observed in 2% (56/2,958) of patients. Missense QKI gene mutation rate was 35.29%. The QKI gene alterations led to deleterious amino acid changes, including P181R, Q112P, and A220G. Altered QKI gene expression was significantly correlated with reduced survival rate (p<0.05).
Conclusion: The QKI gene is most expressed in brain tissues. In patients with gliomas, altered QKI expression/mutation is associated with a shorter survival rate. The findings of this study indicate that the QKI gene mutations can be considered as a potential prognostic biomarker for brain malignancies.
Methods: The Cancer Genome Atlas (TCGA) was investigated for gene expression profile within CNS cancer data. Further analysis was done through cBioPortal and COSMIC to explore the QKI gene mutation(s). Moreover, QKI mRNA levels were evaluated by using SAGE Genie tools. The Kaplan-Meier Plotter was utilized to identify prognostic role of QKI mRNA levels in these cancers.
Results: Higher levels of QKI mRNA were detected in brain cancer tissues. Altered QKI gene expression was observed in 2% (56/2,958) of patients. Missense QKI gene mutation rate was 35.29%. The QKI gene alterations led to deleterious amino acid changes, including P181R, Q112P, and A220G. Altered QKI gene expression was significantly correlated with reduced survival rate (p<0.05).
Conclusion: The QKI gene is most expressed in brain tissues. In patients with gliomas, altered QKI expression/mutation is associated with a shorter survival rate. The findings of this study indicate that the QKI gene mutations can be considered as a potential prognostic biomarker for brain malignancies.
Article Type: Research |
Subject:
Cellular and Molecular Biology
References
1. López de Andrés J, Griñán-Lisón C, Jiménez G, Marchal JA. Cancer stem cell secretome in the tumor microenvironment: a key point for an effective personalized cancer treatment. Journal of hematology & oncology. 2020 Dec;13(1):1-22. [View at Publisher] [DOI] [PMID] [PMCID] [Google Scholar]
2. Shenghui HE, Nakada D, Morrison SJ. Mechanisms of stem cell self-renewal. Annual Review of Cell and Developmental. 2009 Nov 10;25:377-406. [View at Publisher] [DOI] [PMID] [Google Scholar]
3. Shingu T, Ho AL, Yuan L, Zhou X, Dai C, Zheng S, Wang Q, Zhong Y, Chang Q, Horner JW, Liebelt BD. Qki deficiency maintains stemness of glioma stem cells in suboptimal environment by downregulating endolysosomal degradation. Nature genetics. 2017 Jan;49(1):75-86. [View at Publisher] [Google Scholar]
4. Liebelt BD, Shingu T, Zhou X, Ren J, Shin SA, Hu J. Glioma stem cells: signaling, microenvironment, and therapy. Stem cells international. 2016 Oct;2016. [View at Publisher] [DOI] [PMID] [PMCID] [Google Scholar]
5. Alves AL, Gomes IN, Carloni AC, Rosa MN, da Silva LS, Evangelista AF, Reis RM, Silva VA. Role of glioblastoma stem cells in cancer therapeutic resistance: a perspective on antineoplastic agents from natural sources and chemical derivatives. Stem Cell Research & Therapy. 2021 Dec;12(1):1-22. [View at Publisher] [DOI] [PMID] [PMCID] [Google Scholar]
6. Calabrese C, Poppleton H, Kocak M, Hogg TL, Fuller C, Hamner B, Oh EY, Gaber MW, Finklestein D, Allen M, Frank A. A perivascular niche for brain tumor stem cells. Cancer cell. 2007 Jan 1;11(1):69-82. [View at Publisher] [Google Scholar]
7. Li Z, Bao S, Wu Q, Wang H, Eyler C, Sathornsumetee S, Shi Q, Cao Y, Lathia J, McLendon RE, Hjelmeland AB. Hypoxia-inducible factors regulate tumorigenic capacity of glioma stem cells. Cancer cell. 2009 Jun 2;15(6):501-13. [View at Publisher] [Google Scholar]
8. Merlos-Suárez A, Barriga FM, Jung P, Iglesias M, Céspedes MV, Rossell D, Sevillano M, Hernando-Momblona X, da Silva-Diz V, Muñoz P, Clevers H. The intestinal stem cell signature identifies colorectal cancer stem cells and predicts disease relapse. Cell stem cell. 2011 May 6;8(5):511-24. [View at Publisher] [Google Scholar]
9. Li L, Neaves WB. Normal stem cells and cancer stem cells: the niche matters. Cancer research. 2006 May 1;66(9):4553-7. [View at Publisher] [DOI] [PMID] [Google Scholar]
10. Focusing on brain tumours and brain metastasis. Nat Rev Cancer. 2019 Dec ;20(1):1-1. [View at Publisher] [DOI] [PMID]
11. Hanif F, Muzaffar K, Perveen K, Malhi SM, Simjee SU. Glioblastoma multiforme: a review of its epidemiology and pathogenesis through clinical presentation and treatment. Asian Pacific journal of cancer prevention: APJCP. 2017;18(1):3. [PubMed] [Google Scholar]
12. Dunn GP, Rinne ML, Wykosky J, Genovese G, Quayle SN, Dunn IF, Agarwalla PK, Chheda MG, Campos B, Wang A, Brennan C. Emerging insights into the molecular and cellular basis of glioblastoma. Genes & development. 2012 Apr 15;26(8):756-84. [View at Publisher] [DOI] [PMID] [PMCID] [Google Scholar]
13. Rich JN, Eyler CE. Cancer stem cells in brain tumor biology. InCold Spring Harbor symposia on quantitative biology 2008 Jan 1 (Vol. 73, pp. 411-420). Cold Spring Harbor Laboratory Press. [View at Publisher] [DOI] [PMID] [PMCID] [Google Scholar]
14. Vescovi AL, Galli R, Reynolds BA. Brain tumour stem cells. Nature Reviews Cancer. 2006 Jun;6(6):425-36. [View at Publisher] [DOI] [PMID] [Google Scholar]
15. Giese A, Bjerkvig R, Berens ME, Westphal M. Cost of migration: invasion of malignant gliomas and implications for treatment. Journal of clinical oncology. 2003 Apr 15;21(8):1624-36. [DOI] [PMID] [Google Scholar]
16. Hu J, Ho AL, Yuan L, Hu B, Hua S, Hwang SS, Zhang J, Hu T, Zheng H, Gan B, Wu G. Neutralization of terminal differentiation in gliomagenesis. Proceedings of the National Academy of Sciences. 2013 Sep 3;110(36):14520-7. [View at Publisher] [DOI] [PMID] [PMCID] [Google Scholar]
17. Suiko T, Kobayashi K, Aono K, Kawashima T, Inoue K, Ku L, Feng Y, Koike C. Expression of quaking RNA-binding protein in the adult and developing mouse retina. PLoS One. 2016 May 19;11(5):e0156033. [View at Publisher] [DOI] [PMID] [PMCID] [Google Scholar]
18. Sakers K, Liu Y, Llaci L, Lee SM, Vasek MJ, Rieger MA, Brophy S, Tycksen E, Lewis R, Maloney SE, Dougherty JD. Loss of Quaking RNA binding protein disrupts the expression of genes associated with astrocyte maturation in mouse brain. Nature communications. 2021 Mar 9;12(1):1-4. [View at Publisher] [Google Scholar]
19. Chen AJ, Paik JH, Zhang H, Shukla SA, Mortensen R, Hu J, Ying H, Hu B, Hurt J, Farny N, Dong C. STAR RNA-binding protein Quaking suppresses cancer via stabilization of specific miRNA. Genes & development. 2012 Jul 1;26(13):1459-72. [View at Publisher] [DOI] [PMID] [PMCID] [Google Scholar]
20. Darbelli L, Richard S. Emerging functions of the Quaking RNA‐binding proteins and link to human diseases. Wiley Interdisciplinary Reviews: RNA. 2016 May;7(3):399-412. [View at Publisher] [DOI] [PMID] [Google Scholar]
21. Forbes S, Bhamra G, Bamford S, Dawson E, Kok C, Clements J, Menzies A, Teague JW, Futreal PA, Stratton MR. The catalogue of somatic mutations in cancer (COSMIC). Current protocols in human genetics. 2008 Apr;57(1):10-1. [View at Publisher] [DOI] [PMID] [PMCID] [Google Scholar]
22. Gao J, Aksoy BA, Dogrusoz U, Dresdner G, Gross B, Sumer SO, Sun Y, Jacobsen A, Sinha R, Larsson E, Cerami E. Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Science signaling. 2013 Apr 2;6(269):pl1-. [View at Publisher] [DOI] [Google Scholar]
23. Cerami E, Gao J, Dogrusoz U, Gross BE, Sumer SO, Aksoy BA, Jacobsen A, Byrne CJ, Heuer ML, Larsson E, Antipin Y. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer discovery. 2012 May 1;2(5):401-4. [View at Publisher] [DOI] [PMID] [PMCID] [Google Scholar]
24. Velculescu VE, Zhang L, Vogelstein B, Kinzler KW. Serial analysis of gene expression. Science. 1995 Oct 20;270(5235):484-7. [View at Publisher] [DOI] [PMID] [Google Scholar]
25. Szász AM, Lánczky A, Nagy Á, Förster S, Hark K, Green JE, Boussioutas A, Busuttil R, Szabó A, Győrffy B. Cross-validation of survival associated biomarkers in gastric cancer using transcriptomic data of 1,065 patients. Oncotarget. 2016 Aug 2;7(31):49322. [DOI] [PMID] [PMCID] [Google Scholar]
26. Antonov AV, Krestyaninova M, Knight RA, Rodchenkov I, Melino G, Barlev NA. PPISURV: a novel bioinformatics tool for uncovering the hidden role of specific genes in cancer survival outcome. Oncogene. 2014 Mar;33(13):1621-8. [View at Publisher] [Google Scholar]
27. Zheng H, Ying H, Yan H, Kimmelman AC, Hiller DJ, Chen AJ, Perry SR, Tonon G, Chu GC, Ding Z, Stommel JM. p53 and Pten control neural and glioma stem/progenitor cell renewal and differentiation. Nature. 2008 Oct;455(7216):1129-33. [View at Publisher] [DOI] [PMID] [PMCID] [Google Scholar]
28. Chénard CA, Richard S. New implications for the QUAKING RNA binding protein in human disease. Journal of neuroscience research. 2008 Feb 1;86(2):233-42. [View at Publisher] [DOI] [PMID] [Google Scholar]
29. Brennan CW, Verhaak RG, McKenna A, Campos B, Noushmehr H, Salama SR, Zheng S, Chakravarty D, Sanborn JZ, Berman SH, Beroukhim R. The somatic genomic landscape of glioblastoma. Cell. 2014 Apr 24;157(3):753. [Google Scholar]
30. Fuchs E, Tumbar T, Guasch G. Socializing with the neighbors: stem cells and their niche. Cell. 2004 Mar 19;116(6):769-78. [View at Publisher] [Google Scholar]
31. Qaddoumi I, Orisme W, Wen J, Santiago T, Gupta K, Dalton JD, Tang B, Haupfear K, Punchihewa C, Easton J, Mulder H. Genetic alterations in uncommon low-grade neuroepithelial tumors: BRAF, FGFR1, and MYB mutations occur at high frequency and align with morphology. Acta neuropathologica. 2016 Jun;131(6):833-45. [View at Publisher] [Google Scholar]
32. Bandopadhayay P, Ramkissoon LA, Jain P, Bergthold G, Wala J, Zeid R, et al. MYB-QKI rearrangements in angiocentric glioma drive tumorigenicity through a tripartite mechanism. Nat Genet . 2016 Feb; 48(3):273-82 [View at Publisher]
33. Bian Y, Wang L, Lu H, Yang G, Zhang Z, Fu H, Lu X, Wei M, Sun J, Zhao Q, Dong G. Downregulation of tumor suppressor QKI in gastric cancer and its implication in cancer prognosis. Biochemical and biophysical research communications. 2012 May 25;422(1):187-93. [View at Publisher] [Google Scholar]
34. Yu F, Jin L, Yang G, Ji L, Wang F, Lu Z. Post-transcriptional repression of FOXO1 by QKI results in low levels of FOXO1 expression in breast cancer cells. Oncology reports. 2014 Mar 1;31(3):1459-65. [View at Publisher] [DOI] [PMID] [Google Scholar]
35. Yang G, Fu H, Zhang J, Lu X, Yu F, Jin L, Bai L, Huang B, Shen L, Feng Y, Yao L. RNA-binding protein quaking, a critical regulator of colon epithelial differentiation and a suppressor of colon cancer. Gastroenterology. 2010 Jan 1;138(1):231-40. [View at Publisher] [Google Scholar]
36. Zhao YI, Zhang G, Wei M, Lu X, Fu H, Feng F, Wang S, Lu W, Wu N, Lu Z, Yuan J. The tumor suppressing effects of QKI-5 in prostate cancer: a novel diagnostic and prognostic protein. Cancer biology & therapy. 2014 Jan 1;15(1):108-18. [View at Publisher] [DOI] [PMID] [PMCID] [Google Scholar]
37. Lu W, Feng F, Xu J, Lu X, Wang S, Wang L, Lu H, Wei M, Yang G, Wang L, Lu Z. QKI impairs self-renewal and tumorigenicity of oral cancer cells via repression of SOX2. Cancer biology & therapy. 2014 Sep 1;15(9):1174-84. [View at Publisher] [DOI] [PMID] [PMCID] [Google Scholar]
38. Lonsdale J, Thomas J, Salvatore M, Phillips R, Lo E, Shad S, Hasz R, Walters G, Garcia F, Young N, Foster B. The genotype-tissue expression (GTEx) project. Nature genetics. 2013 Jun;45(6):580-5. [View at Publisher] [Google Scholar]
| Rights and permissions | |
 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |